Iovance Biotherapeutics, Inc.
IOVA
$3.89
-$0.15-3.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -71.90M | -91.25M | -111.66M | -116.16M | -78.56M |
| Total Depreciation and Amortization | 12.64M | 11.68M | 11.94M | 11.07M | 17.16M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.99M | 9.41M | 23.08M | 19.03M | 31.56M |
| Change in Net Operating Assets | -7.29M | -8.53M | 9.19M | -17.63M | -43.46M |
| Cash from Operations | -52.57M | -78.70M | -67.45M | -103.69M | -73.30M |
| Capital Expenditure | -9.32M | -10.84M | -7.46M | -6.21M | -4.17M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.10M | 27.86M | 21.30M | 22.08M | 27.85M |
| Cash from Investing | 775.00K | 17.01M | 13.84M | 15.87M | 23.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 56.62M | 88.52M | 13.73M | 148.96M | 3.19M |
| Repurchase of Common Stock | -445.00K | -466.00K | -504.00K | -5.64M | -880.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 56.17M | 88.06M | 13.23M | 143.32M | 2.31M |
| Foreign Exchange rate Adjustments | 577.00K | -680.00K | 739.00K | 508.00K | -1.18M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.96M | 25.69M | -39.64M | 56.00M | -48.49M |